ALISO VIEJO, Calif.--(BUSINESS WIRE)--Brain insulin resistance is an abnormality in Alzheimer’s disease that contributes to neural cell damage and can be detected by a new blood test, according to a multi-site study that was published October 23 in the online issue of The FASEB Journal, The Journal of the Federation of American Societies for Experimental Biology. The highly statistically significant findings were made possible by a novel technique the researchers developed for measuring brain insulin resistance in living patients.
The technique involves using neuron-derived exosomes in the blood to measure insulin resistance in the brain as an indication of early-onset Alzheimer’s disease (AD). This new blood test can accurately reflect development of AD up to 10 years prior to clinical onset, the study said.
Help employers find you! Check out all the jobs and post your resume.
